Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Reports Q4 revenue $4.2B, consensus $4.12B. Richard Francis, Teva‘s (TEVA) President and CEO, said: “2024 marked a transformative year for ...

Wealth host Brad Smith analyzes the latest earnings reports from Wall Street. VF Corp's (VFC) stock climbed following ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

NEW YORK - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported fourth-quarter earnings that beat analyst estimates, but its shares fell sharply as the company's 2025 outlook came in below ...

Israeli generics giant Teva Pharmaceutical Industries today reported results for the year and the quarter ended December 31, ...